Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
1.120
+0.100 (9.80%)
At close: Jul 28, 2025, 4:00 PM
1.110
-0.010 (-0.89%)
Pre-market: Jul 29, 2025, 4:20 AM EDT
Allarity Therapeutics Employees
As of December 31, 2024, Allarity Therapeutics had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$3,429,429
Market Cap
16.89M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7 | 1 | 16.67% |
Dec 31, 2023 | 6 | -3 | -33.33% |
Dec 31, 2022 | 9 | -4 | -30.77% |
Dec 31, 2021 | 13 | -1 | -7.14% |
Dec 31, 2020 | 14 | -2 | -12.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ALLR News
- 13 days ago - Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization - GlobeNewsWire
- 21 days ago - Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer - GlobeNewsWire
- 4 weeks ago - Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer - GlobeNewsWire
- 6 weeks ago - Allarity Therapeutics Announces Changes to Board of Directors - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment - GlobeNewsWire
- 3 months ago - ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PRNewsWire
- 4 months ago - ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PRNewsWire
- 4 months ago - Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission - GlobeNewsWire